Sentence examples for excess supplementary from inspiring English sources

Furthermore, inhibition of telomerase extension was maintained even when non-specific competitor ssDNA was present in orders of magnitude excess (Supplementary Fig. 6).

As expected, the DdGAB peptide inhibited actin-filament nucleation in pyrene assays according to its relatively high affinity to monomers, but did not noticeably sequester actin monomers even at a high molar excess (Supplementary Figure S4), indicating that binding of the GAB to monomers does not interfere with filament elongation.

Taken as a combined group, these 16 DRGs exhibited a mixed pattern (H3, figure 1 with delay d=0) consistent with both patient effect and weekend care contributing to excess mortality (supplementary figure S1 in online appendix).

Most organisms with over-represented GG8g4 pattern are aerobes, whereas virtually no anaerobes have excess of GG8g4 (Supplementary Fig. S1).

The magnitude of negative/positive confounding was assessed by the % of excess risk explained (Supplementary Appendix p. 8).

Over-expressed taperin remains complexed with PP1 during mitosis, as shown by the failure of EYFP-PP1γ to be recruited to metaphase kinetochores in the presence of excess ECFP-taperin (supplementary material Fig. S6A).

Although the plasma concentration of CFH is in substantial molar excess over CFHR1 (Supplementary Material, Fig. S7), it remains possible that they act jointly to suppress complement activation at different steps in the alternative pathway.

FLAG-NKX3.1 was approximately 5-fold in excess over endogenous NKX3.1 (Supplementary Figure S1A) but localized primarily to cell nuclei (Supplementary Figure S1B).

These results did not change when samples were considered analytically, indicating that the non-synonymous variable sites reaching intermediate frequencies are in excess, reproducibly across populations (Supplementary Table S3).

Recombinant VC1059 protein converts DK-CAI-1 to CAI-1 when excess NADPH is present (Supplementary Figure 5).

We completed IC50 measurements in the presence and absence of competitor tRNA (65-fold excess) (Table 1 and Supplementary Figure S-1).